Clinical trial · Interventional
Letrozole as a Treatment of Endometrial Cancer
Predicting Aromatase Inhibitor Responsiveness in Endometrial Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Some cases of endometrial cancer are dependent on estrogen for their growth. Letrozole blocks estrogen production in the body. The purpose of this study is to determine if the investigators can predict which patients might benefit from Letrozole treatment by studying the many different forms of the estrogen receptor molecule that exist within the cancer tissues. To participate in this study, the patients must be 40 years of age or older and have biopsy-proven endometrial carcinoma, either well differentiated or moderately differentiated forms. Also, to be eligible to participate in this study, the patients need to be healthy enough to have a hysterectomy. If the patients are less than age 60, they will need a blood test (FSH) to confirm that they have gone into menopause.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Endometrial Carcinoma | Endometrial Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Letrozole | Drug | Letrozole | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Letrozole
- description
- letrozole 2.5 mg PO daily for 2-3 weeks prior to hysterectomy.
- interventionNames
- Drug: Letrozole
- type
- NO_INTERVENTION
- label
- control
- description
- no treatemtn prior to hysterectomy
Primary outcomes (1)
- measure
- Changes in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer
- timeFrame
- At time of consent and after hysterectomy (generally about 3 weeks)
- description
- Changes in %Ki67 staining cells by immunoperoxidase of paraffin embedded, formalin fixed tissue
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * FIGO grade 1 or 2 endometrioid adenocarcinoma of the endometrium * Post menopausal status must be demonstrated * Signed informed consent Exclusion Criteria: * FIGO grade 3 endometrioid adenocarcinoma or non-endometrioid cancers of the endometrium * Younger than 40 or postmenopausal status not established * Pregnant or breastfeeding
References
Publications (0)
Data not yet available